Abstract
Abnormalities in microRNA expression in tumor cells are widely used as a basis to develop novel therapeutic and diagnostic approaches in oncology. The former mostly aims to target oncogenic microRNAs or to restore expression of microRNAs with tumor suppressor properties in cancer cells. However recently another way of using specific microRNA loss in tumor cells has been suggested. The strategy relies on frequently lost in cancer cells but abundant in cell of normal tissues specific microRNAs, and aims to control unwanted expression of a gene essential for therapeutic action, either therapeutic transgene or essential for viral replication gene in oncolytic viruses, thus minimizing damage to normal tissues and improving safety of cancer gene therapy. Here, history of development and basic principles of the approach as well as current progress in the field are overviewed, with emphasis on benefits brought by the microRNA-based control of specificity for cancer gene therapy and emerging possibility of personification of treatment.
Current Cancer Therapy Reviews
Title:MicroRNAs in Cancer Gene Therapy: Another Look
Volume: 10 Issue: 3
Author(s): Igor V. Korobko
Affiliation:
Keywords: Cancer gene therapy; microRNA; tumor specificity.
Abstract: Abnormalities in microRNA expression in tumor cells are widely used as a basis to develop novel therapeutic and diagnostic approaches in oncology. The former mostly aims to target oncogenic microRNAs or to restore expression of microRNAs with tumor suppressor properties in cancer cells. However recently another way of using specific microRNA loss in tumor cells has been suggested. The strategy relies on frequently lost in cancer cells but abundant in cell of normal tissues specific microRNAs, and aims to control unwanted expression of a gene essential for therapeutic action, either therapeutic transgene or essential for viral replication gene in oncolytic viruses, thus minimizing damage to normal tissues and improving safety of cancer gene therapy. Here, history of development and basic principles of the approach as well as current progress in the field are overviewed, with emphasis on benefits brought by the microRNA-based control of specificity for cancer gene therapy and emerging possibility of personification of treatment.
Export Options
About this article
Cite this article as:
V. Korobko Igor, MicroRNAs in Cancer Gene Therapy: Another Look, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212111836
DOI https://dx.doi.org/10.2174/157339471003150212111836 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products: Perspective of New Pharmacological Agents
Inflammation & Allergy - Drug Targets (Discontinued) Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Anticancer Drugs Targeting the Apoptotic Pathway
Medicinal Chemistry Reviews - Online (Discontinued) DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Sp/KLF Family and Tumor Angiogenesis in Pancreatic Cancer
Current Pharmaceutical Design PHB in Cardiovascular and Other Diseases: Present Knowledge and Implications
Current Drug Targets Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy The Therapeutic Value of Natural Agents to Treat miRNA Targeted Breast Cancer in African-American and Caucasian-American Women
Current Drug Targets Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry Telomeres and Thyroid Cancer
Current Genomics Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Exploring Patterns of Epigenetic Information with Data Mining Techniques
Current Pharmaceutical Design